Education
About Us
Working with TipRanks
Follow Us
MBX Biosciences, Inc. (MBX)
:MBX
MBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.81 - $27.50
Previous CloseN/A
Volume52.29K
Average Volume (3M)1.50M
Market Cap
$675.51M
Enterprise Value$157.38M
Total Cash (Recent Filing)$224.91M
Total Debt (Recent Filing)$650.00K
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Nov 06, 2025EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding33,607,445
10 Day Avg. Volume3,811,922
30 Day Avg. Volume1,498,064
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue708.93
Enterprise Value/Gross Profit-948.09
Enterprise Value/Ebitda-1.78
Forecast
1Y Price Target
$52.50Price Target Upside161.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe canvuparatide Phase 2 Avail trial is expected to achieve a clinically meaningful placebo-adjusted response rate of ~48%, which is seen as positive by key opinion leaders.
Market PotentialThe lead asset canvuparatide (MBX 2109) has significant global peak potential due to its differentiating weekly dosing in the emerging parathyroid hormone replacement market for hypoparathyroidism.
Stock PriceThe release of PRN use data could significantly boost MBX's stock price, with investors expecting substantial appreciation if no safety concerns arise.
Bears Say
Competitive LandscapeSurveyed investors believe that an unadjusted response rate of 55% for canvuparatide is not seen as competitive, regardless of PRN use data disclosure.
Trial ComparisonsCaution is advised when comparing canvu's trial results to Yorvipath due to design differences, making direct comparisons challenging.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $4.81 and its highest was $27.50 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $675.51M.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 40 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.155.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.7.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 33,607,445 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went down -4.627%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
MBX Biosciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.50 (161.19% Upside)
$52.50 (161.19% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 70%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 17.4%
Last 30 Days ▲ 18.5%
Last 30 Days ▲ 18.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.17%
12-Months-Change
Fundamentals
Return on Equity
-56.28%
Trailing 12-Months
Asset Growth
268.18%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc. (MBX) is a biotechnology company focused on the discovery and development of peptide therapeutics to address unmet needs in endocrine disorders. The company leverages its proprietary platform to create novel therapies aimed at improving the lives of patients with complex hormonal conditions. MBX's core products are in various stages of clinical development, targeting specific endocrine diseases where current treatment options are limited or inadequate.
MBX Stock 12 Month Forecast
Average Price Target
$52.50
▲(161.19% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
Currently, No data available
---